Mustang Bio: Up as FDA greenlights cancer drug trial

Mustang Bio

10/05/2021 12:58

** Drug developer's  MBIO.O  shares up ~6% at $3.2 premarket
    ** U.S. FDA accepts MBIO's application to begin an early
stage clinical trial for its experimental treatment, MB-106, for
a type of non-Hodgkin lymphoma (NHL) and chronic lymphocytic
leukemia (CLL)  urn:newsml:reuters.com:*:nGNX8Ll7mG
    ** NHL is among the most common cancers in the United
States, accounting for about 4% of all cancers, and CLL accounts
for about one-third of the new cases of leukemia - MBIO
    ** Co says it plans to begin enrolling patients in the trial
in Q3 this year
    ** Up to Friday's close, MBIO down ~19.4% YTD

    <^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
BUZZ-Ultragenyx's genetic disease treatment front-runner among
rivals - Truist     urn:newsml:reuters.com:*:nL4N2J4267
    ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^>
 (Reporting by Manojna Maddipatla in Bengaluru)
 ((manojna.kalyani@thomsonreuters.com; within the U.S. +1 646
223 8780, outside the U.S. +91  80 6749 1692))